Dermatology
Partner With Us
Advertisement
Conexiant chevron_right Dermatology chevron_right Bimekizumab Sustains Psoriasis Response for 3 Years
From the Journals

Bimekizumab Sustains Psoriasis Response for 3 Years

A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.

Conexiant
Full Article Summary Notecard
  1. 743 patients were randomized to bimekizumab or secukinumab.
  2. After 3 years, PASI 100 was achieved by 68.8% of patients.
  3. The most common adverse event was nasopharyngitis.
  4. Serious infection rates were stable.
  5. 6 deaths were reported during the study. 

Source: BJD

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.